|
1.
|
Guo X and Cui Z: Current diagnosis and
treatment of pancreatic cancer in China. Pancreas. 31:13–22. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Willett CG, Daly WJ and Warshaw AL: CA
19–9 is an index of response to neoadjunctive chemoradiation
therapy in pancreatic cancer. Am J Surg. 172:350–352. 1996.
|
|
3.
|
Goonetilleke KS and Siriwardena AK:
Systematic review of carbohydrate antigen (CA 19–9) as a
biochemical marker in the diagnosis of pancreatic cancer. Eur J
Surg Oncol. 33:266–270. 2007.PubMed/NCBI
|
|
4.
|
Marrelli D, Caruso S, Pedrazzani C, et al:
CA19-9 serum levels in obstructive jaundice: clinical value in
benign and malignant conditions. Am J Surg. 198:333–339. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Grønborg M, Bunkenborg J, Kristiansen TZ,
et al: Comprehensive proteomic analysis of human pancreatic juice.
J Proteome Res. 3:1042–1055. 2004.
|
|
6.
|
Cecconi D, Palmieri M and Donadelli M:
Proteomics in pancreatic cancer research. Proteomics. 11:816–828.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hugli TE: Structure and function of the
anaphylatoxins. Springer Semin Immunopathol. 7:193–219. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Scholz W, McClurg MR, Cardenas GJ, et al:
C5a-mediated release of interleukin 6 by human monocytes. Clin
Immunol Immunopathol. 57:297–307. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wang W, Abbruzzese JL, Evans DB, et al:
The nuclear factor-kappa B RelA transcription factor is
constitutively activated in human pancreatic adenocarcinoma cells.
Clin Cancer Res. 5:119–127. 1999.PubMed/NCBI
|
|
10.
|
Habermann JK, Roblick UJ, Luke BT, et al:
Increased serum levels of complement C3a anaphylatoxin indicate the
presence of colorectal tumors. Gastroenterology. 131:1020–1029.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Pickering MC, Botto M, Taylor PR, et al:
Systemic lupus erythematosus, complement deficiency, and apoptosis.
Adv Immunol. 76:227–324. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Einav S, Pozdnyakova OO, Ma M and Carroll
MC: Complement C4 is protective for lupus disease independent of
C3. J Immunol. 168:1036–1041. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Fujita T, Hara A and Yamazaki Y: The value
of acute-phase protein measurements after curative gastric cancer
surgery. Arch Surg. 134:73–75. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Greenow K, Pearce NJ and Ramji DP: The key
role of apolipoprotein E in atherosclerosis. J Mol Med (Berl).
83:329–342. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Trompet S, Jukema JW, Katan MB, et al:
Apolipoprotein e genotype, plasma cholesterol, and cancer: a
Mendelian randomization study. Am J Epidemiol. 170:1415–1421. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Trost Z, Marc J, Sok M and Cerne D:
Increased apolipoprotein E gene expression and protein
concentration in lung cancer tissue do not contribute to the
clinical assessment of non-small cell lung cancer patients. Arch
Med Res. 39:663–667. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Grant WB: A multicountry ecological study
of risk-modifying factors for prostate cancer: apolipoprotein E
epsilon4 as a risk factor and cereals as a risk reduction factor.
Anticancer Res. 30:189–199. 2010.PubMed/NCBI
|
|
18.
|
Andreotti G, Chen J, Gao YT, et al:
Polymorphisms of genes in the lipid metabolism pathway and risk of
biliary tract cancers and stones: a population-based case-control
study in Shanghai, China. Cancer Epidemiol Biomarkers Prev.
17:525–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Moore LE, Brennan P, Karami S, et al:
Apolipoprotein E/C1 locus variants modify renal cell carcinoma
risk. Cancer Res. 69:8001–8008. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Beppu T, Gil-Bernabe P, Boveda-Ruiz D, et
al: High incidence of tumors in diabetic thrombin activatable
fibrinolysis inhibitor and apolipoprotein E double-deficient mice.
J Tromb Haemost. 8:2514–2522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Mrkonjic M, Chappell E, Pethe VV, et al:
Association of apolipoprotein E polymorphisms and dietary factors
in colorectal cancer. Br J Cancer. 100:1966–1974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Grønborg M, Kristiansen TZ, Iwahori A, et
al: Biomarker discovery from pancreatic cancer secretome using a
differential proteomic approach. Mol Cell Proteomics. 5:157–171.
2006.PubMed/NCBI
|
|
23.
|
Yu KH, Rustgi AK and Blair IA:
Characterization of proteins in human pancreatic cancer serum using
differential gel electrophoresis and tandem mass spectrometry. J
Proteome Res. 4:1742–1751. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Gillard BK, Lin HY, Massey JB and Pownall
HJ: Apolipoproteins A-I, A-II and E are independently distributed
among intracellular and newly secreted HDL of human hepatoma cells.
Biochim Biophys Acta. 1791:1125–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Huvila J, Brandt A, Rojas CR, et al: Gene
expression profiling of endometrial adenocarcinomas reveals
increased apolipoprotein E expression in poorly differentiated
tumors. Int J Gynecol Cancer. 19:1226–1231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Martínez-Clemente M, Ferré N,
González-Périz A, et al: 5-lipoxygenase deficiency reduces hepatic
inflammation and tumor necrosis factor alpha-induced hepatocyte
damage in hyperlipidemia-prone ApoE-null mice. Hepatology.
51:817–827. 2010.PubMed/NCBI
|
